Published trials of TACE for HCC are often not registered and subject to outcome reporting bias.

ABSTRACT:

Background & aims

In 2005, the registration of all randomised controlled trials (RCTs) before enrolment of participants became a condition for publication by the International Committee of Medical Journal Editors to increase transparency in trial reporting. Among RCTs on transarterial chemoembolisation (TACE) for the treatment of hepatocellular carcinoma (HCC) published after 2007, we assess the proportion that were registered and compare registered primary outcomes (PO) with those reported in publications to determine whether primary outcome reporting bias favoured significant outcomes.

Methods

We searched MEDLINE and EMBASE for reports of RCTs evaluating TACE for HCC treatment between 1 September 2007 and 31 March 2018. Registration and publication information for each inc

SUBMITTER: Gregory J 

PROVIDER: S-EPMC7804986 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature